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Abstract
Osteoprotegerin (OPG), a member of the tumor necrosis factor (TNF) receptor superfamily,
contributes determinatively to the bone remodeling as well as to the pathogenetic mechanism of
bone malignancies and disorders of mineral metabolism. There is additional evidence that OPG can
promote cell survival by inhibiting TNF-related apoptosis-inducing ligand (TRAIL)-induced
apoptosis. A number of recent in vitro, in vivo and clinical studies have defined the role of the RANK/
RANKL/OPG pathway in skeletal and vascular diseases. These works were the milestone of the
deep understanding of the mechanism of OPG. This review provides an overview of the potential
innovative therapeutic strategies of OPG in metastatic breast and prostate carcinoma, multiple
myeloma, postmenopausal osteoporosis, glucocorticoid-induced osteoporosis and rheumatoid
arthritis. Special reference is given to the increasing evidence that RANKL and OPG may link the
skeletal with the vascular system.
Introduction
The key factor and dominant mediator of osteoclast differ-
entiation, activation and survival is the Receptor Activator
of NFkB Ligand (RANKL), which binds to its receptor
(RANK) on osteoclast precursor cells and controls osteo-
clastogenesis and bone resorption. Osteoprotegerin
(OPG), a secreted TNF receptor member that functions as
a decoy of RANKL, regulates negatively this interaction [1-
3]. Thereby inhibits osteoclast development and activa-
tion [1-4]. Understanding these molecular mechanisms of
bone metabolism is crucial for developing novel drugs for
treating such diseases [5]. Several studies in a variety of
animal models have proved not only the dominance of
RANKL blockade with OPG in inhibiting osteoclastogen-
esis and bone resorption, but also the role of deregulation
of the RANK/RANKL/OPG system in the pathophysiology
of multiple bone remodeling disorders such as osteoporo-
sis, glucocorticoid-induced bone loss, erosive arthritis
including rheumatoid arthritis, hypercalcemia of malig-
nancy, Paget's disease of the bone and bone metastasis
[6]. Moreover, clinical studies in post-menopausal
women have shown that OPG can reduce the bone turno-
ver [2,3]. These different experimental and clinical studies
shed light on the fact that designing novel drugs that tar-
get RANKL-RANK and their signalling pathways in osteo-
clasts could potentially revolutionize the treatment of
many diseases [6].
Except from its ability to inhibit osteoclastic activity, OPG
seems also to play a key role on cell survival, via its inter-
action with TNF-related apoptosis-inducing ligand
(TRAIL) [7,8]. TRAIL is a member of TNF superfamily. It is
secreted by monocytes and seems to transduce apoptotic
signals. More specifically, TRAIL binds to at least two
membrane receptors (DR4 and DR5) and activates the
death signaling pathway common to the TNF- family
[7,8].
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To date data show that OPG is a soluble receptor for
TRAIL. Emery et al in their study have long demonstrated
that OPG can bind to TRAIL in vitro[9]. Perhaps this inter-
action inhibits the binding of TRAIL to its death-activating
receptors and therefore provides cells that produce OPG
with a survival advantage [1,9]. More recent studies have
also shown that in vitro OPG (through the inhibition of
TRAIL- induced apoptosis) could be a survival factor for
prostate cancer cells [10], breast cancer cells [11] and mul-
tiple myeloma cells [12] (figure 1).
Despite the fact that till now there are not many data
about OPG-TRAIL interaction in vivo, the exact regulating
of the concentration, timing and location of expression of
OPG and TRAIL in tissue microenvironment might deter-
mine the effects of their interactions in vivo [8]. OPG rep-
resents therefore a novel therapeutic option based on the
remarkable advances occurring in the fields of cellular and
molecular biology as applied to research in molecular
medicine [13]. In the present review we want therefore to
present the therapeutic potential of OPG for different dis-
eases based on its molecular mode of action.
Bone malignancies
In patients with cancer, metastasis represents a major
cause of morbidity and mortality. Bone is nowadays
among the most frequent sites of hematogenous tumor
metastasis in human body, representing around 20-40%
of all sites of metastasis. Clinically, bone metastases cause
severe complications (such as bone pain and fractures)
The OPG/RANK/RANKL system and its interaction with TRAIL Figure 1
The OPG/RANK/RANKL system and its interaction with TRAIL. RANKL binds to RANK on osteoprogenitor cells 
and controls osteoclastogenesis and bone resorption. OPG regulates negatively this interaction and therefore inhibits osteo-
clast development and activation. TRAIL is being secreted by monocytes and is responsible for their ability to induce the apop-
totic mechanisms of tumor cells. OPG facilitates the survival of prostate cancer cells due to its ability to bind to and inhibit the 
TRAIL death-activating receptors.Cancer Cell International 2009, 9:26 http://www.cancerci.com/content/9/1/26
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and usually indicate a worse prognosis for the patient.
Histologically, bone metastases are traditionally divided
in osteolytic (where bone resorption is stimulated) and
osteoblastic (where new bone formation is enhanced).
However, today it is well known that in most osseous
metastasis it's rather the balance between bone lysis and
formation that is deregulated, leading to an unbalanced
bone remodeling process and therefore to mixed lesions
[1].
Bone pain, which represents one of the most severe com-
plications of bone metastases, can be minimized by OPG.
Honore et al. have proved that OPG blocks behaviors
indicative of pain in mice with bone cancer [14]. Excessive
tumor-induced bone destruction is involved in the gener-
ation of bone cancer pain and OPG by reducing bone
resorption may provide an effective treatment for this
common human condition [14].
In treating of metastatic bone disease, the primary goals
are the preventing a bone lesion from developing and lim-
iting the progression of an established bone metastasis.
However, the currently available therapies for bone
metastasis such as bisphosphonates, radiotherapy, radi-
opharmaceuticals and surgery focus only on symptomatic
management [15,16]. However, biophosphates - for
example - block not only bone resorption but also tumor-
cell mitosis and stimulate tumor-cell apoptosis. Bisphos-
phonates also alleviate the above mentioned bone pain
[17,18]. Additionally, OPG- like peptidomimetics are also
effective in suppressing bone resorption in patients with
tumor-induced bone disease [19,20]. Anti-RANKL anti-
bodies, such as denosumad, represent a new class of
RANKL inhibitors that are characterized by high specifi-
city for RANKL and so they prevent RANKL from binding
to its receptor and stimulating osteoclasts resulting in the
reduction in bone resorption [21,22].
Prostate cancer
Prostate cancer is among the malignancies that have great
avidity to bone [1,5]. OPG has been shown to be secreted
by prostate cancer cells [10]. It can bind to RANKL and
prevent osteoclastogenesis [23,24]. It is also estimated
that in vitro OPG can protect the tumor cells from apopto-
sis, via its ability to inhibit TRAIL (TNF- related Apoptosis
Inducing Ligand) and the apoptotic mechanisms it acti-
vates [11,10,25]. On the contrary in vivo OPG was shown
to inhibit the survival of prostate cancer cells in bone
[23,26]. Recent in vivo studies also show that OPG can
inhibit RANKL-induced cancer cell migration to the bone.
A possible mechanism is that RANKL can induce prostate
cancer cell migration by binding to RANK which is
expressed on the tumor cells [27,28]. OPG binds to
RANKL and blocks its interaction with RANK inhibiting
RANKL-mediated cell migration to the bone [28]. This
effect is not observed in other tissues, except from the
bone. This tissue-specific inhibition of prostate cancer cell
migration might be additionally partly due to other fac-
tors related to the local bone microenvironment [27,28].
However, it is not yet clear whether this ability of OPG to
inhibit the development of osseous lesions could have
any clinical implications in the treatment of patients with
tumor-related bone disease [26].
In clinical level, several studies have shown that serum
OPG concentrations are significantly higher in patients
with prostate cancer [29], and even higher in those with
advanced disease [30], suggesting that prostate cancer
cells over-secrete OPG. Such data indicate a potential role
of serum OPG as a surrogate marker of the disease pro-
gression or early relapse in patients with prostate cancer.
Breast cancer
Concerning the role of OPG in breast cancer metastases to
bone, it has been shown that breast cancer cells can pro-
duce OPG in vitro [11]. This seems to be very important,
as OPG can protect breast cancer cells from undergoing
TRAIL-induced apoptosis [11,21,31]. On the other hand,
OPG treatment in animal models of breast cancer inhib-
ited the development of osseous lesions [32,33] and the
growth of cancer cells in the bone [32]. This was a result
of the treatment with high dose of OPG (up to 25 mg/kg)
as controlled after 4 weeks with a Faxitron X-ray system
and histological analysis [32]. Clinical studies do not yet
exist. But these experimental data indicate that OPG could
perhaps be a potential therapeutic option for the treat-
ment of bone lysis observed in patients with metastatic
breast cancer, but further studies are essential to establish
this role.
Multiple myeloma
Multiple myeloma is a malignant clonal proliferation of
B-lymphocyte- derived plasma cells, characterized by its
ability to develop osteolytic bone lesions, via the induc-
tion of osteoclastic bone resorption [34].
Recent studies have revealed that myeloma cells do not
express OPG, but via intracellular interactions with oste-
oblasts and Bone marrow stem cells (BMSCs) can down-
regulate the OPG released from these cells [35]. Moreover,
they can bind, internalize and degrade OPG in vitro [34].
This process leads to decreased OPG concentrations in
bone marrow micro-environment and therefore to
increased osteoclast activation via the RANKL pathway
[34]. In the 5TMM murine model of multiple myeloma,
treatment with OPG protected the mice from myeloma-
induced bone disease as measured after 4 weeks by the
radiographic Faxitron x-ray system [35,36]. Recent experi-
mental data also suggest that multiple myeloma cells
enhance the expression of RANKL and reduce that of OPGCancer Cell International 2009, 9:26 http://www.cancerci.com/content/9/1/26
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in their microenvironment [37]. This seems to be a result
of interaction between multiple myeloma cells and
BMSCs indicating that multiple myeloma cells can cause
an imbalance of OPG/RANKL axis and that this dysregyla-
tion is involved in the pathogenesis of multiple myeloma
disease [37]. On the other hand, OPG is shown to prevent
TRAIL-induced apoptosis in human myeloma cell lines
[9]. It is therefore intriguing to investigate why the down-
regulation of an anti-apoptotic factor may take part in the
development of myeloma bone disease.
Clinical studies have shown that the serum concentra-
tions of OPG are lower in patients with multiple mye-
loma, and even lower in those with evidence of bone
lesions suggesting that OPG plasma concentrations may
be related with the degree of osteolysis [38]. In a phase I
clinical trial, the treatment of patients with a single-dose
of OPG was shown to inhibit significantly bone lysis, as
56 days after the treatment the levels of bone resorption
markers (and especially of urinary N- telopeptide/creat-
ine) were decreased [10,39].
These clinical and also experimental data strongly suggest
that deregulation of the OPG expression is involved in
multiple myeloma. OPG could be not only a possible sur-
rogate marker for multiple myeloma in the management
of patients with, but also a potential therapeutic target for
the treatment of the multiple myeloma [34,40].
It should also be mentioned that during the last years
there has also been increasing interest in the role of Dick-
kopf 1 (DKK-1) in multiple myeloma. DKK-1 is a soluble
inhibitor of Wnt signaling pathway, which prevents oste-
oblast differentiation. DKK-1 can also inhibit the expres-
sion of OPG in osteoblasts [41]. Therefore, DKK-1 both
directly and indirectly enhances the osteoclastic activity in
bone microenvironment. DKK-1 is secreted by myeloma
cells and is over-expressed in patients with advanced mye-
loma bone disease, as shown by measurement of DKK-1
levels in both bone microenvironment and serum [42].
Overall, these data suggest that DKK-1 might partly be
responsible for bone lysis observed in multiple myeloma
disease [41,42].
Hypercalcemia of malignancy
By binding and neutralizing RANKL, OPG diminishes
osteoclast formation and activity resulting in blocking
bone resorption in animal models of hypercalcemia of
malignancy [43-45]. Studies have indicated that OPG,
given either at the onset of hypercalcemia or after it had
occurred (hypercalcemia over 3-5 days), blocks tumor-
induced bone resorption and hypercalcemia and there-
fore leads to normalization of blood calcium within 48
hours [43-45] suggesting an effective method for curing
this paraneoplasmatic syndrome. OPG can effectively
reverse hypercalcemia in less than 3-5 days in most
patients [44].
Disorders of mineral metabolism
As it has been already mentioned, OPG regulates nega-
tively the interaction between RANKL and its receptor
RANK and therefore inhibits osteoclast development and
activation. This is the main pathway that explains that the
RANK/RANKL/OPG system contributes significantly to
the pathophysiological mechanism of several bone disor-
ders by regulating osteoclastogenesis [2] and may repre-
sent the key factor for the discovery of the therapeutic
properties of OPG for these diseases.
Postmenopausal osteoporosis
The discovery of the determinative contribution of the
RANK/RANKL/OPG system in the osteoclastogenesis
indicates its role in the pathogenesis of postmenopausal
osteoporosis [2,46]. Recent studies have shown that the
up-regulation of RANKL on bone marrow cells induced by
estrogen deficiency in postmenopausal women is respon-
sible for the bone resorption [47]. By blocking the interac-
tion of RANKL with RANK in vivo, OPG reduces the
osteoresorptive results of this signaling pathway [48]. Fur-
thermore, several investigations using a mouse ovariec-
tomy model of estrogen deficiency-induced osteoporosis
concluded to the fact that OPG not only prevents bone
loss but also increases bone mineral density leading to
osteopetrosis when over-expressed [48-50]. It has been
also shown that a single injected dose of OPG in post-
menopausal women causes rapidly and profoundly
reducing bone turnover after 12 hours as measured by the
decreasement of the biochemical markers, urinary N-tel-
opeptide (NTX) and deoxypyridinoline (DPD), which are
stable collagen degradation products [51].
Low-dosage intermittent parathyroid hormone (PTH)
treatment has an anabolic effect on the skeleton and this
ability makes PTH a promising therapeutic treatment for
osteoporosis. However, intermittent administered PTH
also stimulates bone resorption and therefore can cause
hypercalcemia, which can be inhibited by co-administra-
tion of PTH and antiresorptives [48,52]. A significantly
greater and more rapid increase in bone mineral density is
proved by OPG-PTH co-treatment rather than administer-
ing the agents separately [49]. Therefore the combination
of OPG and PTH represents an effective therapeutic
approach to treating or reversing severe osteoporosis in
humans. A further advantage of PTH combined with OPG
is the inhibition of the hypercalcemic effects of PTH treat-
ment [48,52].
Glucocorticoid-induced bone loss
Osteoporosis is a well known side-effect of long-term glu-
cocorticoid treatment, but the precise underlying mecha-Cancer Cell International 2009, 9:26 http://www.cancerci.com/content/9/1/26
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nism remains unclear. Recently, it has been proved that
glucocorticoids affect the RANK/RANKL/OPG pathway by
stimulating RANKL expression by osteoblasts and inhibit-
ing OPG synthesis and thereby resulting in osteoclast dif-
ferentiation, activation and survival [53-55]. These
findings explain that glucocorticoid-induced bone loss
develops rapidly because of the combination of increscent
of bone resorption and suppression of bone formation
[2,53-55], suggesting that the reversal of this bone loss is
possible by treating with OPG. These findings may open
new therapeutic options to effectively treat the glycocorti-
coid-induced osteoporosis.
Rheumatoid arthritis
Rheumatoid arthritis is a chronic disease which is charac-
terized by progressive synovial inflammation and joint
destruction. Recently, it has been demonstrated that the
RANK/RANKL/OPG system participates in the pathophys-
iological mechanism of focal and generalized bone loss in
rheumatoid arthritis as it is described below [2,4]. Oste-
oblastic-stromal cells, synovial fibroblasts and activated T-
cells are important inducers of RANKL expression leading
to loss of the RANKL/OPG-balance, resulting in the oste-
oclastogenic proceeds in erosive arthritis [4,56]. Interest-
ingly, studies have shown that higher serum levels of OPG
and RANKL are present in patients with rheumatoid
arthritis than in healthy people, but the ratio of OPG/
RANKL is similar [40, 41, 42]. These data conclude to the
fact that anti-TNF therapy normalizes the OPG/RANKL
balance stimulating the bone erosion in arthritis [56-58].
In a T-cell-dependent model of rat adjuvant arthritis char-
acterized by severe joint inflammation, bone and cartilage
destruction and crippling, blocking of RANKL through
treatment with OPG at the onset of disease prevents bone
and cartilage destruction but not inflammation [59].
These results show that both systemic and local T-cell acti-
vation leads to RANKL production and therefore bone
loss. This study of Kong et al. demonstrates nicely that
bone remodelling and bone loss are controlled by a bal-
ance between RANKL and OPG [59].
Fractures
Although the effects of OPG on fracture healing are not so
clear, it has been proved that expression of OPG and
RANKL in callus tissue is involved in the mechanism of
endochondral resorption and remodeling [4]. The clinical
study of Vinther et al. including 80 patients has demon-
strated that although OPG treatment impairs remodeling
of healing fractures and decreases the mechanical quality
of the callus tissue, OPG does not influence the strength
of the fractures in total [4].
Renal osteodystrophy
In patients with uremia either increased or suppressed
bone turnover can be observed [2]. However, secondary
hyperparathyroidism is the most common type of renal
osteodystrophy and is characterized by PTH-related bone
loss. OPG serum levels are increased in patients with
chronic kidney disease [2] and it might inhibit osteoclas-
togenesis and bone resorption induced by PTH in patients
with uremia [60]. Therefore, OPG serum concentrations
could possibly be used as surrogate markers of the pro-
gression of bone disease in patients with uremia, but fur-
ther studies are needed to establish this role [2,61].
Vascular Diseases
Several epidemiological studies have shown that oste-
oporosis and vascular calcification could be associated
[2,62,63] and share many common risk factors [62].
Although the mechanisms responsible for this phenome-
non are not clear yet [64], OPG is today believed to be an
important mediator of it. More specifically, it is estimated
that a deregulation of calcium allocation results in its
movement from the bone to the endothelium of the ves-
sels through mechanisms that involve OPG [62].
It is also interesting that endothelial cells (ECs) and vascu-
lar smooth muscle cells (VSMCs) produce and express all
members of the OPG/RANK/RANKL-axis [62]. RANKL
produced by ECs and VSMCs interacts with RANK- recep-
tors on the surface of ECs and might participate in the
process of atherosclerosis via mechanisms that are today
under investigation. In a recent in vitro study, RANKL
caused a dose-dependent increase of calcification in
VSMCs, which was inhibited by OPG. The researchers
hypothesize that RANKL binds to RANK and through the
activation of an intracellular pathway leads to an
increased production of bone morphogenetic protein 4
(BMP4) in VSMCs, which induces vascular calcification
[65].
OPG is believed to antagonize RANKL actions in vessels as
well [62]. However its role on vascular tissue is much
more complicated, as its production can either be induced
or down-regulated in response to various inflammatory
mediators, and can therefore affect the process of vascular
calcification in multiple ways [62].
Vascular calcification
The actions of OPG have been studied in a number of ani-
mal models [62,66-68]. In vivo studies in OPG knockout
mice indicate calcification of the aorta and renal arteries
[62,66]. These are both sites where OPG is normally
expressed [67]. These findings suggest that OPG produced
in these arteries might protect them from early calcifica-
tion and that its lack or deficiency might take part in path-
ological artery calcification [67].Cancer Cell International 2009, 9:26 http://www.cancerci.com/content/9/1/26
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Such a vascular protective role is also suggested by a study
in which treatment by OPG could inhibit the vascular cal-
cification induced by warfarin and vitamin D [68]. Warfa-
rin causes calcification by inhibiting the vitamin K-
dependent carboxilation of matrix Cla protein (MGP).
Injections of OPG in rats treated previously with warfarin
inhibited arterial calcification [68].
On the second animal model of this study, treatment with
high doses of vitamin D caused extended calcification of
the arteries in rats, which was also inhibited by injections
of OPG [68]. The researchers suppose that the vascular-
protective role of OPG in their animal models is a result
of two possible mechanisms; on the one hand limited
bone resorption and on the other hand direct promotion
of the expression of calcification inhibitors (e.g. MGP) in
vascular cells [68].
On the contrary, clinical studies have revealed that serum
OPG concentrations are increased in patients with cardio-
vascular disease and may serve as an independent risk fac-
tor of cardiovascular events [63,69,70]. Moreover, its key-
role in the regulation of the inflammation, proliferation
and apoptosis of various cell types in tissues where it is
expressed (e.g. the bone) indicate that OPG may also par-
ticipate in such procedures in the vascular tissue as well
[63]. Therefore, further researches and essential in order
to establish a possible role of OPG not only as a marker,
but also as a therapeutic target of cardiovascular disease.
Conclusion
The RANK/RANKL/OPG system plays a determinative role
in the pathophysiology of different bone and vascular dis-
eases and increases our understanding of the contribution
of OPG to the treatment of those disorders. However,
greater insights into the healing mechanism of OPG con-
cerning bone diseases would lead to new therapeutic
approaches that limit or prevent such disorders. There-
fore, further researches are indispensable, since questions
related to the therapeutic role of OPG have to be
answered, but OPG remains a breakthrough in the treat-
ment of bone disorders.
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